ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …

BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease
(CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major …

Although several classes of pharmacotherapy are available for type 2 diabetes, glycaemic
control is often hampered by medication‐related adverse effects and contraindications such …

Aims Glucose-lowering, glucagon-like peptide-1 (GLP-1) receptor agonists reduce
incidence of major cardiovascular (CV) events in patients with Type 2 diabetes mellitus …

Background Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2)
inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with …

Clinical question What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-
2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual …

The latest recommendations from the American Diabetes Association and the European
Association for the Study of Diabetes prioritize the use of drugs with proven cardiovascular …

Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1
receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults …

Background Recent trials suggested that glucagon-like peptide-1 receptor agonists (GLP-1
RAs) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors reduced cardiovascular …